Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 561 to 570 of 654 total matches.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
. Whether
ospemifene is safe for use in women with or at risk
for breast cancer remains to be established ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Three New Drugs for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
safety of using them concurrently has not been established. Cholestyramine and presumably colestipol ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Drug Interactions with Grapefruit Juice
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004 (Issue 1173)
; clinical importance not established
Itraconazole (Sporanox) Possible decreased effect Avoid concurrent use ...
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Palladone for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
was established by an unpublished 4week, randomized, double-blind trial in 221 patients
with chronic moderate ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Sildenafil (Revatio) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
with the other therapies for this condition remains to
be established.
1. Sildenafil for pulmonary hypertension. Med Lett ...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006 (Issue 1226)
the prevalence of pertussis and prevent infection
of unvaccinated children remains to be established.
1 ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Abatacept (Orencia) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006 (Issue 1229)
established
rheumatoid arthritis: results from the AIM trial [presentation
1494]. Annual meeting ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Transdermal Methylphenidates (Daytrana) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
and clonidine
(Catapres, and others), but cause and effect have not
been established.
7
DOSAGE ...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Fish Oil Supplements
The Medical Letter on Drugs and Therapeutics • Jul 17, 2006 (Issue 1239)
; whether they could cause clinically significant bleeding has not been established.
CONCLUSION — Omega-3 ...
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential human nutrients. The main dietary source of PUFAs is fatty fish such as salmon, but small amounts may be converted from α-linolenic acid in nuts, seeds, and plant oils such as canola or flaxseed oil. An increased intake of these fatty acids has been shown to modify membrane function, inhibit thrombus formation, decrease inflammation, lower plasma triglycerides, and alter the electrical activity of the myocardium.
MoviPrep: A New Bowel Prep for Colonoscopy
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
is
established that limits sodium absorption and promotes
fluid efflux into the gut lumen.
CLINICAL STUDIES ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.